Reuters
Published Dec 16, 2021 02:54PM ET
Updated Dec 16, 2021 03:36PM ET
(Reuters) - Novavax (NASDAQ:NVAX)'s COVID-19 vaccine could receive approval from Europe's drug regulator next week and subsequently an emergency use listing from the World Health Organization, the Financial Times reported on Thursday, sending shares of the U.S. drugmaker up 7%.
A WHO approval could come once the health body issued its own emergency use listing or if the EMA gave it a conditional marketing authorization, the newspaper reported, citing people familiar with the matter.
That could pave the way for the company and its partner, Serum Institute of India, to ship doses to the COVAX program, providing another vaccine to low-income countries.
The WHO said on Thursday that it would reveal its position over the vaccine in the coming days, following an expert group meeting.
The protein-based vaccine by Novavax in June was shown to be more than 90% effective, including against a variety of concerning coronavirus variants, in a large, late-stage U.S. trial.
Novavax's shot received its first authorization in Indonesia last month and is awaiting approval in Japan, where it would be manufactured and distributed by Takeda Pharmaceutical.
The Maryland-based company has also said it could begin commercial manufacturing of a vaccine tailored to the highly transmissible Omicron coronavirus variant in January.
The drugmaker is currently testing the effectiveness of its existing two-dose vaccine against Omicron.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.